Latest Conference Articles

This interview at Maui Derm 2026 highlights notable takeaways regarding psoriasis treatment strategies and emerging therapies.

In this analysis presented at Maui Derm, indirect comparisons were made between risankizumab and icotrokinra in patients with psoriasis.

This Q&A interview with Drew Kuraitis, MD, PhD, highlights Kuraitis’s talk on strategies for cutaneous adverse events linked with therapeutic agents in oncology.

Recent pooled analysis data suggest consistently low adverse event rates with upadacitinib over 7 years for patients with atopic dermatitis.

The Maui Derm Hawaii 2026 conference featured a poster presentation highlighting recent phase 3 findings on risankizumab in pediatric patients.

At the Maui Derm Hawaii 2026 conference, Lawrence Eichenfield, MD, spoke about highlights from his talk, ‘Atopic Dermatitis and Pruritus: Current Concepts and Therapeutics for 2026.’

The safety and efficacy of risankizumab versus deucravacitinib were evaluated among patients with moderate psoriasis and no prior biologic use.

This Q&A interview with Dawn Eichenfield, MD, PhD, highlights notable takeaways from her session at Maui Derm Hawaii titled ‘Pediatric Dermatology 2026.’

This interview with Stein Gold continues her discussion of new and emerging psoriasis therapies in 2026.

At the 2026 Maui Derm Hawaii meeting, recent data on icotrokinra’s use in patients with psoriasis were highlighted.

Neal Bhatia, MD, speaks in this interview regarding his discussion at Maui Derm Hawaii of new and emerging therapies in dermatology.

This interview from the Maui Derm 2026 conference features Lawrence Eichenfield, MD, discussing takeaways from his talk ‘Acne and Rosacea: Update 2026.’

This interview segment continues with Paul Nghiem, MD, PhD, highlighting notable insights from his session on cutaneous oncology.

Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.

In a talk given at the Maui Derm 2026 conference, Neal Bhatia, MD, and Ted Rosen, MD, speak on new and upcoming therapies for dermatologic diseases for 2026.

Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

In this interview, Siegel highlights key points presented in his Maui Derm 2026 talk, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

This summary of the 2026 Maui Derm Conference highlights some of the sessions and interviews to look forward to.

Al-Samkari discusses a potentially novel use for bevacizumab in improving outcomes for patients with lesions from non-HHT etiologies.

Al-Samkari discusses the slew of HHT-related complications, their frequency, and their severity, highlighting the need for more active intervention.

Zorrilla discusses the safety and efficacy of a series of minor surgeries in patients with hemophilia A/B currently taking fitusiran to control AT levels.

Sohail discusses the promising results from this retrospective cohort study which aims to put longstanding concerns about worsening infection to bed.

Malec discusses the XTEND-ed trial, which proved the efficacy and tolerability of efanesoctocog alfa in adults and children with hemophilia A.

Pustake highlights the reticence with which clinicians should approach providing platelet transfusion to patients.

Kuter discusses the efficacy and safety of rilzabrutinib in sustaining platelet responses and symptom improvement over the LUNA3 long-term extension.

Phase 2b REZOLVE-AD trial data show rezpegaldesleukin improves skin symptoms and asthma control in adults with moderate-to-severe atopic dermatitis.

Jain describes the phase 3 WIL-33 trial, which marked the first test of pdVWF/FVIII in adolescent patients aged <6 years.

A prediction model ties emergency visits and opioid doses with return visits in children with sickle cell disease pain.